Brentuximab Vedotin Plus AVD in Non-bulky Limited Stage Hodgkin Lymphoma

Trial Profile

Brentuximab Vedotin Plus AVD in Non-bulky Limited Stage Hodgkin Lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Feb 2018

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Dacarbazine; Doxorubicin; Vinblastine
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Jan 2018 Status changed from active, no longer recruiting to completed.
    • 10 Jun 2017 Biomarkers information updated
    • 08 May 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top